Pack de 10 frascos6 em estoqueEconomize 19%Retatrutide 50 mg
Peptídeo de pesquisa triagonista de GLP-1 / GIP / glucagon
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Somente para uso em pesquisa. Este composto é vendido estritamente para pesquisa in vitro e fins laboratoriais e não se destina ao consumo humano nem a uso terapêutico. Ao comprar, você confirma que é um pesquisador qualificado e concorda com o nosso aviso legal completo.
Restam apenas 6 packs
Peptídeo de pesquisa agonista de triplo receptor, estudado pelos efeitos combinados sobre as vias de sinalização de GLP-1, GIP e glucagon em aplicações de pesquisa metabólica.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mecanismo
Estudado pelo agonismo simultâneo dos receptores de GLP-1, GIP e glucagon. Pesquisa associada a marcadores de taxa metabólica, saciedade e gasto energético em populações de estudo.
Verificado por HPLC em relação a uma especificação de pureza ≥99 %. Testado de forma independente por laboratórios terceiros credenciados.
Retatrutide — perguntas frequentes
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guias relacionados com Retatrutide
Os investigadores também exploram
Pack de 10 frascosEconomize 22%MOTS-c
Pó liofilizado10 mg · 2 strengths
Peptídeo metabólico de origem mitocondrial
Em 2 combinações
Pack de 10 frascosEconomize 17%5-Amino-1MQ
Pó liofilizado50 mg · 3 strengths
Composto de pesquisa inibidor de NNMT
Pack de 10 frascosEconomize 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Transportador mitocondrial de ácidos graxos
Em 1 combinação